Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$22.21
-1.0%
$24.62
$22.21
$53.96
$1.05B0.72496,020 shs464,402 shs
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
$0.00
$4.35
$11.97
$1.01B4.52528,025 shs1.43 million shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$36.59
-0.1%
$32.86
$29.31
$61.38
$4.37B0.591.53 million shs1.16 million shs
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$1.36
$1.21
$0.66
$1.55
$309.13M1.861.45 million shs1.05 million shs
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$2.05
-11.3%
$1.73
$0.60
$3.08
$167.40M1.4394,280 shs392,373 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
-0.71%-4.83%-15.70%-4.59%-39.33%
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.00%0.00%0.00%0.00%0.00%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
+6.95%+6.61%+10.56%-3.22%-33.23%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
+7.09%+12.40%+2.26%+75.03%+13.33%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
+5.00%+0.87%-17.50%+242.63%+51.97%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
4.4296 of 5 stars
3.12.00.03.72.34.21.3
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/AN/AN/AN/AN/AN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
4.1794 of 5 stars
4.52.00.04.61.50.80.0
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3.7754 of 5 stars
3.51.00.04.72.01.70.0
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
2.9789 of 5 stars
3.73.00.00.02.51.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
2.25
Hold$32.3345.58% Upside
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.00
N/AN/AN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.93
Moderate Buy$70.9293.83% Upside
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3.00
Buy$7.33439.22% Upside
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
3.33
Buy$6.00192.68% Upside

Current Analyst Ratings Breakdown

Latest CYTK, IMAB, CNTTF, GOSS, and AMPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
7/9/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
6/27/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $5.00
6/9/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$71.00 ➝ $53.00
5/29/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$103.00 ➝ $84.00
5/16/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $8.00
5/16/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.00
5/14/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
5/13/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/12/2025
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral$45.00 ➝ $30.00
5/8/2025
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$40.00 ➝ $35.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$731.97M1.43$4.91 per share4.52$15.23 per share1.46
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
$15.96M0.00N/AN/AN/ANaN
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$19.22M227.38N/AN/A($1.15) per share-31.82
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$124.59M2.48N/AN/A$0.13 per share10.46
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/AN/AN/AN/A$2.47 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$159.52M$2.768.056.755.8919.38%22.20%10.40%8/6/2025 (Estimated)
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A$0.07137.180.00N/AN/AN/AN/AN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$589.53M-$5.29N/AN/AN/A-3,201.47%N/A-43.75%8/6/2025 (Estimated)
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$56.53M-$0.23N/AN/AN/A-41.12%-128.98%-15.52%8/11/2025 (Estimated)
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
-$22.23MN/A0.00N/AN/AN/A-19.81%-18.63%8/27/2025 (Estimated)

Latest CYTK, IMAB, CNTTF, GOSS, and AMPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$0.71N/AN/AN/A$173.42 millionN/A
5/15/2025Q1 2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$0.18-$0.16+$0.02-$0.16$3.95 million$9.89 million
5/6/2025Q1 2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
N/AN/AN/AN/AN/A
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/AN/AN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
N/AN/AN/AN/AN/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
0.80
2.95
2.02
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
5.99
5.99
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
6.70
5.71
5.71
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/A
22.35
22.35

Institutional Ownership

CompanyInstitutional Ownership
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
65.09%
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.08%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
81.23%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38.38%

Insider Ownership

CompanyInsider Ownership
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
27.50%
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.70%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
6.70%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
22.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
2,02847.14 million34.18 millionOptionable
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A105.61 millionN/ANot Optionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
250119.43 million116.20 millionOptionable
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
180227.30 million212.07 millionOptionable
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38081.66 million63.61 millionOptionable

Recent News About These Companies

I-Mab (NASDAQ:IMAB) Given Buy Rating at HC Wainwright
I-Mab (NASDAQ:IMAB) Price Target Raised to $5.00
I-Mab regains compliance with Nasdaq’s listing rule

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amphastar Pharmaceuticals stock logo

Amphastar Pharmaceuticals NASDAQ:AMPH

$22.21 -0.23 (-1.02%)
Closing price 04:00 PM Eastern
Extended Trading
$22.21 0.00 (0.00%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

CannTrust stock logo

CannTrust OTCMKTS:CNTTF

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$36.59 -0.04 (-0.11%)
Closing price 04:00 PM Eastern
Extended Trading
$36.48 -0.11 (-0.30%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Gossamer Bio stock logo

Gossamer Bio NASDAQ:GOSS

$1.36 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.34 -0.02 (-1.10%)
As of 06:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

I-Mab stock logo

I-Mab NASDAQ:IMAB

$2.05 -0.26 (-11.26%)
Closing price 04:00 PM Eastern
Extended Trading
$2.06 +0.01 (+0.24%)
As of 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.